Skip to main content

VALIDACION DE LOS HETEROMEROS ENTRE RECEPTORES DE DOPAMINA D1 Y DE ADENOSINA A1 COMO UNA NUEVA DIANA TERAPEUTICA PARA EL TRATAMIENTO DE DISFUNCIONES MOTORAS MEDULARES Y CEREBR

SAF2017-87629-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2017
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Orally active peptide vector allows using cannabis to fight pain while avoiding side effects

  • Gallo, María, 1989-
  • Moreno, Estefanía
  • Defaus, Sira
  • Ortega Alvaro, Antonio
  • Gonzalez, Angel
  • Robledo, Patricia, 1958-
  • Cavaco, Marco
  • Neves, Vera
  • Castanho, Miguel A.R.B.
  • Casadó, Vicent
  • Pardo Carrasco, Leonardo
  • Maldonado, Rafael, 1961-
  • Andreu Martínez, David
The activation of cannabinoid CB1 receptors (CB1R) by Δ9-tetrahydrocannabinol (THC), the main component of Cannabis sativa, induces analgesia. CB1R activation, however, also causes cognitive impairment via the serotonin 5HT2A receptor (5HT2AR), a component of a CB1R-5HT2AR heteromer, posing a serious drawback for cannabinoid therapeutic use. We have shown that peptides reproducing CB1R transmembrane (TM) helices 5 and 6, fused to a cell-penetrating sequence (CPP), can alter the structure of the CB1R-5HT2AR heteromer and avert THC cognitive impairment while preserving analgesia. Here, we report the optimization of these prototypes into drug-like leads by (i) shortening the TM5, TM6, and CPP sequences, without losing the ability to disturb the CB1R-5HT2AR heteromer, and (ii) extensive sequence remodeling to achieve protease resistance and blood-brain barrier penetration. Our efforts have culminated in the identification of an ideal candidate for cannabis-based pain management, an orally active 16-residue peptide preserving THC-induced analgesia., Rhodes Pharmaceuticals (L.P., Coventry, R.I., USA; 2016–2017), Marie Skłodowska-Curie Research and Innovation Staff Exchange (call H2020-MSCA-RISE-2014, 2015–2019), the Spanish Ministry of Economy and Innovation with FEDER funds (SAF2017-87629-R, PID2019-109240RB-I00), and the Fundació Bancària La Caixa (CaixaImpulse 2018 call; 2018–2020).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Reversible photocontrol of dopaminergic transmission in wild-type animals

  • Matera, Carlo
  • Calvé Pérez, Pablo, 1993-
  • Casadó-Anguera, Verònica
  • Sortino, Rosalba
  • Gomila, Alexandre M.J.
  • Moreno, Estefanía
  • Gener, Thomas
  • Delgado-Sallent, Cristina
  • Nebot Forcada, Pau
  • Costazza, Davide
  • Conde-Berriozabal, Sara
  • Masana, Mercè
  • Hernando, Jordi
  • Casadó, Vicent
  • Puig Velasco, María Victoria
  • Gorostiza, Pau
Understanding the dopaminergic system is a priority in neurobiology and neuropharmacology. Dopamine receptors are involved in the modulation of fundamental physiological functions, and dysregulation of dopaminergic transmission is associated with major neurological disorders. However, the available tools to dissect the endogenous dopaminergic circuits have limited specificity, reversibility, resolution, or require genetic manipulation. Here, we introduce azodopa, a novel photoswitchable ligand that enables reversible spatiotemporal control of dopaminergic transmission. We demonstrate that azodopa activates D1-like receptors in vitro in a light-dependent manner. Moreover, it enables reversibly photocontrolling zebrafish motility on a timescale of seconds and allows separating the retinal component of dopaminergic neurotransmission. Azodopa increases the overall neural activity in the cortex of anesthetized mice and displays illumination-dependent activity in individual cells. Azodopa is the first photoswitchable dopamine agonist with demonstrated efficacy in wild-type animals and opens the way to remotely controlling dopaminergic neurotransmission for fundamental and therapeutic purposes., This research was funded by EU Horizon 2020 Framework Programme for Research and Innovation: Human Brain Project WaveScalES, Specific Grant Agreement 2 No. 785907 and Specific Grant Agreement 3 No. 945539; NEUROPA project, Grant Agreement No. 863214; DEEPER project ICT-36-2020-101016787; European Union Regional Development Fund within the framework of the ERDF Operational Program of Catalonia 2014-2020: CECH project; Ministry of Science and Innovation DEEP RED grant PID2019-111493RB-I00 funded by MCIN/AEI/10.13039/501100011033; Ministerio de Economía y Competitividad and European Regional Development Funds: Grant no. SAF2017-87629-R to V.C., SAF2016-80726-R to M.V.P., SAF2017-88076-R to M.M.; AGAUR/Generalitat de Catalunya: CERCA Programme; Generalitat de Catalunya: Grant no. 2017-SGR-1442 to P.G., 2017-SGR-1497 to V.C., 2017-SGR-210 to M.V.P., and 2017-SGR-00465 to J.H.; Fundaluce and “la Caixa” foundations: ID 100010434, grant agreement LCF/PR/HR19/52160010.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Identification of bip as a cb1 receptor-interacting protein that fine-tunes cannabinoid signaling in the mouse brain

  • Costas-Insua, Carlos
  • Moreno, Estefanía
  • Maroto, Irene B.
  • Ruiz-Calvo, Andrea
  • Bajo-Grañeras, Raquel
  • Martín-Gutiérrez, David
  • Diez-Alarcia, Rebeca
  • Vilaró, Maria Teresa
  • Cortés, Roser
  • García-Font, Nuria
  • Martín, Ricardo
  • Espina, Marc
  • Botta, Joaquín
  • Ginés, Silvia
  • McCormick, Peter J.
  • Sánchez-Prieto, José
  • Galve-Roperh, Ismael
  • Mengod Los Arcos, Guadalupe
  • Urigüen, Leyre
  • Marsicano, Giovanni
  • Bellocchio, Luigi
  • Canela, Enric I.
  • Casadó, Vicent
  • Rodríguez-Crespo, Ignacio
  • Guzmán, Manuel
Cannabinoids, the bioactive constituents of cannabis, exert a wide array of effects on the brain by engaging Type 1 cannabinoid receptor (CB1R). Accruing evidence supports that cannabinoid action relies on context-dependent factors, such as the biological characteristics of the target cell, suggesting that cell population-intrinsic molecular cues modulate CB1R-dependent signaling. Here, by using a yeast two-hybrid-based high-throughput screening, we identified BiP as a potential CB1R-interacting protein. We next found that CB1R and BiP interact specifically in vitro, and mapped the interaction site within the CB1R C-terminal (intracellular) domain and the BiP C-terminal (substrate-binding) domain-a. BiP selectively shaped agonist-evoked CB1R signaling by blocking an "alternative" Gq/11 protein-dependent signaling module while leaving the "classical" Gi/o protein-dependent inhibition of the cAMP pathway unaffected. In situ proximity ligation assays conducted on brain samples from various genetic mouse models of conditional loss or gain of CB1R expression allowed to map CB1R-BiP complexes selectively on terminals of GABAergic neurons. Behavioral studies using cannabinoid- treated male BiP1/2 mice supported that CB1R-BiP complexes modulate cannabinoid-evoked anxiety, one of the most frequent undesired effects of cannabis. Together, by identifying BiP as a CB1R-interacting protein that controls receptor function in a signaling pathway- and neuron population-selective manner, our findings may help to understand the striking context-dependent actions of cannabis in the brain., This work was supported by Spanish Ministerio de Ciencia e Innovación Grants RTI2018-095311-B-I00 to M.G., SAF-2017-87629-R to E.I.C. and V.C., PID2019-106404RB-I00 to L.U., BFU 2017-83292-R to J.S.-P., and RTI2018-094374-B-I00 to S.G.; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas Grant PI2018/01 to M.G., S.G., and G. Mengod; and UK Research and Innovation Biotechnology and Biological Sciences Research Council Grant BB/R006946/1 to P.J.M., L.B., and G. Marsicano were supported by Institut National de la Santé et de la Recherche Médicale. C.C.-I. and I.B.M. were supported by contracts from Spanish Ministerio de Universidades (Formación de Profesorado Universitario Program, references FPU16/02593 and FPU15/01833, respectively). R.B.-G. was supported by a contract from Spanish Ministerio de Ciencia e Innovación Juan de la Cierva Program., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Orally active peptide vector allows using cannabis to fight pain while avoiding side effects

  • Gallo, María, 1989-
  • Moreno, Estefanía
  • Defaus, Sira
  • Ortega Alvaro, Antonio
  • Gonzalez, Angel
  • Robledo, Patricia, 1958-
  • Cavaco, Marco
  • Neves, Vera
  • Castanho, Miguel A.R.B.
  • Casadó, Vicent
  • Pardo Carrasco, Leonardo
  • Maldonado, Rafael, 1961-
  • Andreu Martínez, David
The activation of cannabinoid CB1 receptors (CB1R) by Δ9-tetrahydrocannabinol (THC), the main component of Cannabis sativa, induces analgesia. CB1R activation, however, also causes cognitive impairment via the serotonin 5HT2A receptor (5HT2AR), a component of a CB1R-5HT2AR heteromer, posing a serious drawback for cannabinoid therapeutic use. We have shown that peptides reproducing CB1R transmembrane (TM) helices 5 and 6, fused to a cell-penetrating sequence (CPP), can alter the structure of the CB1R-5HT2AR heteromer and avert THC cognitive impairment while preserving analgesia. Here, we report the optimization of these prototypes into drug-like leads by (i) shortening the TM5, TM6, and CPP sequences, without losing the ability to disturb the CB1R-5HT2AR heteromer, and (ii) extensive sequence remodeling to achieve protease resistance and blood-brain barrier penetration. Our efforts have culminated in the identification of an ideal candidate for cannabis-based pain management, an orally active 16-residue peptide preserving THC-induced analgesia., Rhodes Pharmaceuticals (L.P., Coventry, R.I., USA; 2016–2017), Marie Skłodowska-Curie Research and Innovation Staff Exchange (call H2020-MSCA-RISE-2014, 2015–2019), the Spanish Ministry of Economy and Innovation with FEDER funds (SAF2017-87629-R, PID2019-109240RB-I00), and the Fundació Bancària La Caixa (CaixaImpulse 2018 call; 2018–2020).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Reversible photocontrol of dopaminergic transmission in wild-type animals

  • Matera, Carlo
  • Calvé Pérez, Pablo, 1993-
  • Casadó-Anguera, Verònica
  • Sortino, Rosalba
  • Gomila, Alexandre M.J.
  • Moreno, Estefanía
  • Gener, Thomas
  • Delgado-Sallent, Cristina
  • Nebot Forcada, Pau
  • Costazza, Davide
  • Conde-Berriozabal, Sara
  • Masana, Mercè
  • Hernando, Jordi
  • Casadó, Vicent
  • Puig Velasco, María Victoria
  • Gorostiza, Pau
Understanding the dopaminergic system is a priority in neurobiology and neuropharmacology. Dopamine receptors are involved in the modulation of fundamental physiological functions, and dysregulation of dopaminergic transmission is associated with major neurological disorders. However, the available tools to dissect the endogenous dopaminergic circuits have limited specificity, reversibility, resolution, or require genetic manipulation. Here, we introduce azodopa, a novel photoswitchable ligand that enables reversible spatiotemporal control of dopaminergic transmission. We demonstrate that azodopa activates D1-like receptors in vitro in a light-dependent manner. Moreover, it enables reversibly photocontrolling zebrafish motility on a timescale of seconds and allows separating the retinal component of dopaminergic neurotransmission. Azodopa increases the overall neural activity in the cortex of anesthetized mice and displays illumination-dependent activity in individual cells. Azodopa is the first photoswitchable dopamine agonist with demonstrated efficacy in wild-type animals and opens the way to remotely controlling dopaminergic neurotransmission for fundamental and therapeutic purposes., This research was funded by EU Horizon 2020 Framework Programme for Research and Innovation: Human Brain Project WaveScalES, Specific Grant Agreement 2 No. 785907 and Specific Grant Agreement 3 No. 945539; NEUROPA project, Grant Agreement No. 863214; DEEPER project ICT-36-2020-101016787; European Union Regional Development Fund within the framework of the ERDF Operational Program of Catalonia 2014-2020: CECH project; Ministry of Science and Innovation DEEP RED grant PID2019-111493RB-I00 funded by MCIN/AEI/10.13039/501100011033; Ministerio de Economía y Competitividad and European Regional Development Funds: Grant no. SAF2017-87629-R to V.C., SAF2016-80726-R to M.V.P., SAF2017-88076-R to M.M.; AGAUR/Generalitat de Catalunya: CERCA Programme; Generalitat de Catalunya: Grant no. 2017-SGR-1442 to P.G., 2017-SGR-1497 to V.C., 2017-SGR-210 to M.V.P., and 2017-SGR-00465 to J.H.; Fundaluce and “la Caixa” foundations: ID 100010434, grant agreement LCF/PR/HR19/52160010.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Orally Active Peptide Vector Allows Using Cannabis to Fight Pain While Avoiding Side Effects

  • Gallo, Maria|||0000-0001-9099-7235
  • Moreno, Estefanía|||0000-0002-2491-5753
  • Defaus, Sira|||0000-0002-3106-458X
  • Ortega-Alvaro, Antonio
  • Gonzalez, Angel|||0000-0002-2284-8307
  • Robledo, Patricia
  • Cavaco, Marco|||0000-0002-0938-9038
  • Neves, Vera|||0000-0002-2989-7208
  • Castanho, Miguel A. R. B.|||0000-0001-7891-7562
  • Casadó, Vicent|||0000-0002-1764-3825
  • Pardo Carrasco, Leonardo|||0000-0003-1778-7420
  • Maldonado, Rafael|||0000-0002-4359-8773
  • Andreu Martínez, David|||0000-0002-6317-6666
The activation of cannabinoid CB receptors (CBR) by Δ 9 -tetrahydrocannabinol (THC), the main component of Cannabis sativa, induces analgesia. CBR activation, however, also causes cognitive impairment via the serotonin 5HT receptor (5HTR), a component of a CBR-5HTR heteromer, posing a serious drawback for cannabinoid therapeutic use. We have shown that peptides reproducing CBR transmembrane (TM) helices 5 and 6, fused to a cell-penetrating sequence (CPP), can alter the structure of the CBR-5HTR heteromer and avert THC cognitive impairment while preserving analgesia. Here, we report the optimization of these prototypes into drug-like leads by (i) shortening the TM5, TM6, and CPP sequences, without losing the ability to disturb the CBR-5HTR heteromer, and (ii) extensive sequence remodeling to achieve protease resistance and blood-brain barrier penetration. Our efforts have culminated in the identification of an ideal candidate for cannabis-based pain management, an orally active 16-residue peptide preserving THC-induced analgesia.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Nk3R blockade has sex-divergent effects on memory in mice

  • Florido Torres, Antonio Luis|||0000-0001-6184-0706
  • Moreno, Estefanía|||0000-0002-2491-5753
  • Canela, Enric I|||0000-0003-4992-7440
  • Andero Galí, Raül|||0000-0003-3641-8903
Memory consolidation is a process required for the formation of long-term memories. The G-protein-coupled receptor (GPCR) neurokinin-3-receptor (Nk3R) and its interactions with sex hormones seem important for the modulation of fear memory consolidation: Nk3R antagonism in male mice impairs fear memory, but enhances it in females. However, the involvement of the Nk3R as a modulator of other memories in both sexes remains unexplored. We use the novel object recognition paradigm to test the effect of a systemic blockade of Nk3R during memory consolidation. Further, we assess the expression of estrogen receptor α, estrogen receptor β, and androgen receptor and heterodimerization with Nk3R in the medial prefrontal cortex (mPFC) and dorsal hippocampus (DH) of mice. Nk3R systemic antagonism elicited decreased memory consolidation in males while it enhanced it in females during proestrus. Nk3R analysis in the different subregions of the mPFC and the DH showed a higher expression in males than females. Moreover, females presented upregulation of the androgen receptor in the CA1 and the estrogen receptor beta in the cingulate cortex, CA1, and dentate gyrus. Overall, males presented an upregulation of the estrogen receptor alpha. We also explored the heterodimerization of GCPR membrane sex hormone receptors with the Nk3R. We found a higher percentage of Nk3R-membrane G-protein estrogen receptors heterodimers in the prelimbic cortex of the mPFC in females, suggesting an interaction of estradiol with Nk3R in memory consolidation. However, males presented a higher percentage of Nk3R-membrane G-protein androgen receptors heterodimers compared to females, pointing to an interaction of testosterone with Nk3R in memory consolidation. These data propose novel ideas on functional interactions between Nk3R, sex hormones, estrogen receptors, and androgen receptors in memory consolidation.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Reversible Photocontrol of Dopaminergic Transmission in Wild-Type Animals

  • Matera, Carlo|||0000-0001-6939-3859
  • Calvé, Pablo
  • Casadó-Anguera, Verònica|||0000-0001-8532-2954
  • Sortino, Rosalba|||0000-0002-8854-6782
  • Gomila, Alexandre|||0000-0003-0867-6171
  • Moreno, Estefanía|||0000-0002-2491-5753
  • Gener, Thomas Adrien|||0000-0001-9209-9228
  • Delgado-Sallent, Cristina|||0000-0002-2202-1043
  • Nebot, Pau
  • Costazza, Davide|||0000-0002-7876-0291
  • Conde Berriozabal, Sara|||0000-0002-3712-8046
  • Masana, Mercè|||0000-0003-1392-4774
  • Hernando, Jordi|||0000-0002-1126-4138
  • Casadó, Vicent|||0000-0002-1764-3825
  • Puig Velasco, Maria Victoria|||0000-0002-1490-4153
  • Gorostiza, Pau|||0000-0002-7268-5577
Understanding the dopaminergic system is a priority in neurobiology and neuropharmacology. Dopamine receptors are involved in the modulation of fundamental physiological functions, and dysregulation of dopaminergic transmission is associated with major neurological disorders. However, the available tools to dissect the endogenous dopaminergic circuits have limited specificity, reversibility, resolution, or require genetic manipulation. Here, we introduce azodopa, a novel photoswitchable ligand that enables reversible spatiotemporal control of dopaminergic transmission. We demonstrate that azodopa activates D1-like receptors in vitro in a light-dependent manner. Moreover, it enables reversibly photocontrolling zebrafish motility on a timescale of seconds and allows separating the retinal component of dopaminergic neurotransmission. Azodopa increases the overall neural activity in the cortex of anesthetized mice and displays illumination-dependent activity in individual cells. Azodopa is the first photoswitchable dopamine agonist with demonstrated efficacy in wild-type animals and opens the way to remotely controlling dopaminergic neurotransmission for fundamental and therapeutic purposes.